Merck & Co Inc (NYSE:MRK) | Merck hits a new high as analyst sees opening for new cancer drug

[at MarketWatch] – An upgrade to Merck & Co. drives the drug maker’s shares to a new 52-week high even though the rest of the market stumbles out of the gate. Read more . . . → Read More: Merck & Co Inc (NYSE:MRK) | Merck hits a new high as analyst sees opening for new cancer drug Similar Articles: Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies Merck & Co. Inc. (NYSE:MRK) – Germany’s Merck looks for deals to lift U.S. drug sales Company Update: Johnson & Johnson (NYSE:JNJ) – AstraZeneca to co-promote J&J prostate cancer drug in Japan